Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Colquhoun

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
European Heart Journal|May 4, 2004
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID studyDavid Colquhoun, Anthony Keech, David Hunt, et al.
Lancet (London, England)|December 13, 2025
WHO's category mistakeSusan Bewley, James May, Les Rose, et al.
Australian Family Physician|June 13, 2009
Dietary intervention to lower serum cholesterolPeter Clifton, David Colquhoun, Claire Hewat, et al.
Atherosclerosis|October 13, 2005
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID studyRoland Stocker, Christine Pollicino, Craig A Gay, et al.
Heart, Lung & Circulation|July 1, 2015
Clinical Exercise Stress Testing in Adults (2014)David Colquhoun, Ben Freedman, David Cross, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
BMJ (Clinical Research Ed.)|September 19, 2014
Time to halt an out of control trial with ineffective oversightSusan Bewley, Les Rose, Peter Gøtzsche, et al.
Diabetes Care|September 30, 2003
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech, David Colquhoun, James Best, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Structural abnormalities of the AChR caused by mutations underlying congenital myasthenic syndromesDavid Beeson, Richard Webster, John Ealing, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
European Heart Journal|May 4, 2004
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID studyDavid Colquhoun, Anthony Keech, David Hunt, et al.
Lancet (London, England)|December 13, 2025
WHO's category mistakeSusan Bewley, James May, Les Rose, et al.
Australian Family Physician|June 13, 2009
Dietary intervention to lower serum cholesterolPeter Clifton, David Colquhoun, Claire Hewat, et al.
Atherosclerosis|October 13, 2005
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID studyRoland Stocker, Christine Pollicino, Craig A Gay, et al.
Heart, Lung & Circulation|July 1, 2015
Clinical Exercise Stress Testing in Adults (2014)David Colquhoun, Ben Freedman, David Cross, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
BMJ (Clinical Research Ed.)|September 19, 2014
Time to halt an out of control trial with ineffective oversightSusan Bewley, Les Rose, Peter Gøtzsche, et al.
Diabetes Care|September 30, 2003
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech, David Colquhoun, James Best, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Structural abnormalities of the AChR caused by mutations underlying congenital myasthenic syndromesDavid Beeson, Richard Webster, John Ealing, et al.
Pageof 10